Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Zhongyu Yuan"'
Autor:
Zhongyu Yuan, MMed, Michal L. Melamed, MD, MHS, Tripti Singh, MD, Sandesh Parajuli, MD, Sarah Panzer, MD, Didier Mandelbrot, MD, Brad C. Astor, PhD, MPH
Publikováno v:
Transplantation Direct, Vol 10, Iss 4, p e1600 (2024)
Background. Recurrence of glomerulonephritis (GN) is a significant contributor to long-term allograft failure among kidney transplant recipients (KTRs) with kidney failure because of GN. Accumulating evidence has revealed the role of vitamin D in bot
Externí odkaz:
https://doaj.org/article/fb632d19107e42a18b6e49748668217d
Autor:
Zefeng Wang, Zhongyu Yuan, Haiwei Li, Ke Zhang, Hongkai Zhang, Xiaoyan Li, Changhua Wang, Yilun Tian, Yiqing Shen, Xiaoping Zhang, Yongquan Wu
Publikováno v:
Frontiers in Surgery, Vol 11 (2024)
We report three patients with screw-in lead perforation in the right atrial free wall not long after device implantation. All the patients complained of intermittent stabbing chest pain associated with deep breathing during the implantation. The “d
Externí odkaz:
https://doaj.org/article/2710292cda764b82a23896c3f77c6a31
Autor:
Zhongyu Yuan, Chenge Song, Zhangzan Huang, Jia Jia Huang, Zhen-Yu He, Xin Hua, Wen Xia, Xiwen Bi
Publikováno v:
Gland Surg
BACKGROUND: Breast cancer is one of the most common malignancy in women with high mortality rate. Given the growing evidence shows that immune-inflammatory system influences the survival of patients with cancer, we assessed the prognostic significanc
Autor:
Chenge Song, Zhangzan Huang, Jia Jia Huang, Zhen-Yu He, Xiwen Bi, Zhongyu Yuan, Wen Xia, Xin Hua
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 10 (2020)
Frontiers in Oncology, Vol 10 (2020)
Background: Systemic inflammation score (SIS) has been verified as a novel prognostic indicator in several cancer types. However, its prognostic value in breast cancer remains unknown. Furthermore, a nomogram based on SIS is yet to be constructed for
Autor:
Huiping Li, Yongmei Yin, Xiao Jia Wang, Zhongyu Yuan, Cuizhi Geng, Pin Zhang, Xichun Hu, Yongsheng Wang, Jing Cheng, Binghe Xu, Rou-Jun Peng, Zefei Jiang, Qingyuan Zhang, Jian Liu, Baochun Zhang, Zhongsheng Tong, Shude Cui, Shaohua Zhang, Hongming Pan, Hong Zheng, Li Tang, Tao Sun, Yuee Teng, Qiang Yao, Jian Huang, Min Yan, Jinsong Lu, Rongguo Qiu, Junlan Yang, Ping Sun
Publikováno v:
The Lancet Oncology. 18:371-383
Utidelone, a genetically engineered epothilone analogue, has shown promise as a potential treatment for breast cancer in phase 1 and 2 trials. The aim of this phase 3 trial was to compare the efficacy and safety of utidelone plus capecitabine versus
Autor:
Shusen Wang, Xiaoyu Teng, Yin-Duo Zeng, Bing Bai, Zhongyu Yuan, Roujun Peng, Dong-Geng Liu, Tao Qin, Yanxia Shi
Publikováno v:
Archives of Medical Science : AMS
Introduction The aim of the study was to analyze clinicopathologic characteristics and survival and to identify prognostic factors for Chinese patients with HER2-positive metastatic breast cancer. Material and methods A total of 243 patients with HER
Autor:
Yanxia Shi, Qiufan Zheng, Huimin Yuan, Roujun Peng, Quchang Ouyang, Danmei Pang, Fei Xu, Shusen Wang, Zhongyu Yuan, Wen Xia
Publikováno v:
Journal of Clinical Oncology. 35:1066-1066
1066 Background: Fulvestrant is potent for treatment of hormone receptor (HR)-positive advanced breast cancer (ABC); however, few data exist for this regimen as maintenance endocrine treatment after chemotherapy (CT). In our phase 2 trial, we aimed t
Autor:
Cong Xue, Roujun Peng, Qiufan Zheng, Ge Qin, Tao Qin, Zhongyu Yuan, Jia Jia Huang, Yanxia Shi, Xin An, Qianyi Lu, Ruoxi Hong, Wen Xia, Shusen Wang, Fei Xu
Publikováno v:
Journal of Clinical Oncology. 34:e12001-e12001
e12001Background: Endocrine therapy is associated with definite improvements in disease-free survival in hormone receptor-positive breast cancer, but also with many adverse events. We conducted a s...
Publikováno v:
Blood. 126:4601-4601
Neutropenia is common in patients receiving myelotoxic chemotherapy. BenegrastimTM(F-627), a recombinant human G-CSF dimer, is an once-per-cycle therapy for prophylactic neutropenia in cancer patients after chemotherapy. Two phase I dose finding stud
Autor:
Fei Xu, Ge Qin, Xin An, Roujun Peng, Tao Qin, Man Nie, Qiufan Zheng, Zhongyu Yuan, Yanxia Shi, Cong Xue, Shusen Wang, Wen Xia
Publikováno v:
Medicine. 94:e1718
Selective estrogen receptor modulator (SERM)-associated nonalcoholic fatty liver disease (NAFLD) might be related to treatment efficacy in patients with breast cancer because of circulating estrogen antagonism. The aim of the study was to investigate